Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Egalet’s opioid prescription painkiller
In August 2016, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 18-1 to recommend approval of Arymo ER tablets for pain severe enough to require daily,
In August 2016, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 18-1 to recommend approval of Arymo ER tablets for pain severe enough to require daily,
Under the terms of the deal, which is expected to close by the end of next month, Takeda agreed to pay $24 in cash for each Ariad share.
Amgen which filed the lawsuit against the joint developers of Praulent got the injunction in its favor in the US District Court in Delaware. The California based company
The Swiss drugmaker signed a collaboration and option agreement, which is subject to customary closing conditions and regulatory approvals. Ionis developed two investigational antisense therapies, dubbed AKCEA-APO(a)-LRx and
Humira is currently approved in the US, the European Union and other markets for arthritis related problems and other indications. The investigational compound PF-06410293, a monoclonal antibody (mAb), met
BMS’ immuno-oncology agent Opdivo will now be assessed with Janssen’s Darzalex in multiple myeloma, as well as several solid tumor types including including non-small cell lung cancer, pancreatic cancer,
Duzallo, which is a fixed-dose combination of lesinurad and allopurinol, is intended to treat hyperuricemia in patients with uncontrolled gout. The drug is likely to be commercially launched in
The randomized, double-blind, vehicle controlled phase 3 confirmatory study included 744 patients. The primary endpoint of statistically significant improvement in Schirmer's score (a measurement of tear production) was
Ganaxolone is being developed in three different dose forms that include IV, capsule, and liquid, aimed at maximizing therapeutic reach to adult and pediatric patient populations in both acute and chronic
The 16-subject FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) trial will assess 50 mg of CBD in ZYN002 4.2% gel once daily. It